Metabolomics and the Diagnosis of Human Diseases - A Guide to the Markers and Pathophysiological Pathways Affected
Metabolomics and the Diagnosis of Human Diseases - A Guide to the Markers and Pathophysiological Pathways Affected
复制标题
DOI：
10.2174/0929867320666131119124056
复制
发表时间：
2014-03-01
影响因子：
4.1
通讯作者：
Gil-Izquierdo, A.
中科院分区：
文献类型：
--
作者：
Medina, S.;Dominguez-Perles, R.;Gil-Izquierdo, A.
这篇综述旨在作为对多种人类疾病具有重要意义的代谢组学标志物的手册。这是第一份整理近期研究结果的报告，其格式允许通过一种疾病与另一种疾病结果的交叉比较来轻松识别关键代谢物。这项工作中提供的所有数据都是通过之前专门在人体临床试验期间进行的研究获得的。此外，还提供了与所述标记物相关的病理生理学途径的讨论。临床测定侧重于非靶向或靶向代谢组学和代谢物分析（重点测定仅涉及有限的已知生物标志物，对其应用歧视性和生物信息学工具）以及基于临床试验的预测模型。这些数据还强调了在疾病早期阶段被破坏的途径和生物化合物，以帮助阐明目标化合物和所考虑疾病的病理生理学，以便使用非侵入性样本（唾液、痰、血清、血浆、血液、尿液、组织、粪便水或粪便）进行早期预后和诊断。表中详细列出了诊断生物标志物的候选代谢物或生物标志物本身，表明检测到它们的样品类型及其上调或下调（如果计算）。根据分析平台，每项研究得出的代谢物都经过仔细过滤，并进行了生物统计判别分析。在提供的数据池中，显示了根据 Bonferroni 校正、Steel-Dwass t- 或 Wilcoxon 配对检验达到 p=0.05-0.0001 显着性水平的数据。
This review was designed as a handbook of metabolomic markers of high significance for a wide range of human diseases. This is the first report to collate results from recent studies in a format that allows ready identification of key metabolites by cross-comparisons of results from one disease to another. All the data presented in this work were obtained by previous research carried out exclusively during clinical trials in humans. Also, discussion of the pathophysiological pathways linked to the markers described is provided. The clinical assays focused on non-targeted or targeted metabolomics and metabolite profiling (focused assays which only refer to a limited array of known biomarkers, applying discriminatory and bioinformatic tools to them) as well as predictive modelling based on clinical trials. The data also highlight pathways and biological compounds that are disrupted at early stages of the diseases, in order to help elucidate target compounds and the pathophysiology of the considered diseases for early prognosis and diagnosis using noninvasive samples (saliva, sputum, serum, plasma, blood, urine, tissue, faecal water or faeces). In the tables, the candidate metabolites for biomarkers of diagnosis, or the biomarkers themselves, are detailed, indicating the type of sample in which they were detected and their up-or down-regulation (if calculated). The metabolites derived from each study have been filtered carefully, according to the analytical platform, and biostatistical discriminant analyses developed. Among the pool of data provided, those reaching a level of significance of p=0.05-0.0001, according to the Bonferroni correction, Steel-Dwass t- or Wilcoxon matched pair tests, are shown.